|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||11.09 - 11.09|
|52-week range||11.09 - 11.09|
|Beta (5Y monthly)||1.78|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2021 - 14 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. Sangamo management is expected to participate in a panel discussion at 10 a.m. Eastern Time on April 1, 2021.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study partnered with Sanofi. The Committee’s decision to grant Orphan Designation was based in part on early data from three patients that had 52 weeks, 13 weeks, and 29 days of follow-up, respectively.
A look at the shareholders of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) can tell us which group is most powerful...